

Customer No. 22,852
Attorney Docket No. 06969.0032

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)
Ronald K. SCHEULE et al.)
Serial No.: Not Yet Assigned) Group Art Unit:
Filed: August 2, 2001) Examiner:
For: USE OF CATIONIC LIPIDS TO)
GENERATE ANTI-TUMOR)
IMMUNITY)
U.S. NATIONAL PHASE APPLICATION BASED ON PCT/US00/02943

Assistant Commissioner for Patents
Washington, DC 20231
BOX: PCT

Sir:

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97(b)

Pursuant to 37 C.F.R. §§1.56 and 1.97(b), applicants bring to the Examiner's attention the documents listed on attached Form PTO-1449 and cited in the international search report. Copies of the listed documents are attached. Applicants respectfully request that the Examiner consider the documents listed on attached Form PTO-1449 and indicate that they were considered by making an appropriate notation on this form.

This Information Disclosure Statement is being filed with the above-referenced application.

This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each or all of the listed documents are material or constitute "prior art." If the Examiner applies

LAW OFFICES

FINNEGAN, HENDERSON,
FARABOW, GARRETT,
& DUNNER, L.L.P.
1300 I STREET, N. W.
WASHINGTON, DC 20005
202-408-4000

9/890712

Customer No. 22,852
Attorney Docket No. 06969.0032

any of the documents as prior art against any claim in the application and applicants determine that the cited documents do not constitute "prior art" under United States law, applicants reserve the right to present to the office the relevant facts and law regarding the appropriate status of such documents. Applicants further reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

If there is any fee due in connection with the filing of this Statement, please charge the fee to our Deposit Account No. 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,
GARRETT & DUNNER, L.L.P.

Dated: August 2, 2001

By: 
Ernest F. Chapman
Reg. No. 25,961

Enclosures
EFC/FPD/peg

INFORMATION DISCLOSURE CITATION

JC17 Rec'd PCT/PTO 02 AUG 2001

OMB No. 0651-0011

09/890712

Atty. Docket No. 06969.0032	Serial No.
Applicant Ronald K. SCHEULE et al.	
Filing Date August 2, 2001	Group:

U.S. PATENT DOCUMENTS						
Examiner Initial*	Document Number	Issue Date	Name	Class	Sub Class	Filing Dat If Appropriate
	5,747,471	5/5/98	Siegel et al.	514	44	

FOREIGN PATENT DOCUMENTS						
	Document Number	Publication Date	Country	Class	Sub Class	Translation Yes or No
	WO98/10748	3/19/98	WIPO/PCT			
	WO99/66879	12/29/99	WIPO/PCT			
	WO99/61056	12/2/99	WIPO/PCT			
	WO99/61592	12/2/99	WIPO/PCT			
	WO96/02555	2/1/96	WIPO/PCT			
	WO98/02191	1/22/98	WIPO/PCT			
	WO98/49288	11/5/98	WIPO/PCT			

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)	
	J. Bramson, et al., "ACTIVATION OF HOST ANTITUMORAL RESPONSES BY CATIONIC LIPID/DNA COMPLEXES", Cancer Gene Therapy, Vol. 7, No. 3, pp. 353-355, (2000).
	D. Neujahr et al., "IMMUNOSTIMULATORY PROPERTIES OF GENOMIC DNA FROM DIFFERENT BACTERIAL SPECIES", Immunobiol Vol. 200, pp. 106-119, (1999).
	D. Klinman, et al., "CONTRIBUTION OF CpG MOTIFS TO THE IMMUNOGENICITY OF DNA VACCINES", The Journal of Immunology, Vol. 158, pp. 3635-3639, (1997).
	P. Manders et al., "IMMUNOLOGY OF DNA VACCINES: CpG MOTIFS AND ANTIGEN PRESENTATION", Inflamm. res. 49, pp. 199-205, (2000).
	A. Krieg et al., "THE ROLE OF CpG DINUCLEOTIDES IN DNA VACCINES", Trends in Microbiology, Vol. 6, No. 1, pp. 23-27, (1998).

Examiner	Date Considered
<p>*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>	
Form PTO 1449	Patent and Trademark Office - U.S. Department of Commerce